Related Experiment Video
Updated: Sep 28, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
AbioCor totally implantable artificial heart. How will it impact hospitals?
Insights
The AbioCor total artificial heart (TAH) offers improved mobility and reduced infection risk for severe heart failure patients. This wireless, implantable device aims to enable a more normal life, unlike previous TAH designs.
Area of Science:
- Biomedical Engineering
- Cardiovascular Medicine
- Medical Devices
Background:
- Heart transplantation is limited by donor organ scarcity.
- Existing total artificial hearts (TAHs) require external connections, hindering patient mobility and increasing infection risk.
- A fully implantable TAH could significantly improve quality of life for end-stage heart failure patients.
Purpose of the Study:
- To describe the novel AbioCor total artificial heart (TAH) system.
- To evaluate the potential of the AbioCor TAH to overcome limitations of current TAH technology.
- To discuss the clinical impact and future of the AbioCor TAH and related ventricular assist devices (VADs).
Main Methods:
- Description of the AbioCor TAH's wireless power system and internal components.
- Review of clinical trial status and preliminary observations.
- Discussion of potential hospital adoption and comparison with ventricular assist devices (VADs).
Main Results:
- The AbioCor TAH features a transcutaneous energy transfer system, enabling complete patient mobility.
- Elimination of transcutaneous wires significantly reduces the risk of infection associated with previous TAHs.
- The device is currently undergoing clinical trials in the United States.
Conclusions:
- The AbioCor TAH represents a significant advancement in artificial heart technology.
- Its wireless design and reduced infection potential could allow patients a more normal life.
- Further clinical evaluation is necessary to determine its long-term efficacy and impact on cardiac support strategies.
Abstract:
Although heart transplantation remains the most effective treatment for severe heart failure, there are far fewer donor hearts available than there are patients who could benefit from them. One approach to addressing this shortfall is the total artificial heart, or TAH. To date, however, no TAH design has been able to achieve one of the ultimate goals of heart replacement: to allow a patient to live a reasonably normal life without being connected to external machinery. A new design, the AbioCor TAH developed by Abiomed Inc., may make this goal achievable. Thanks to a power system that transfers energy through the skin without the aid of wires, the AbioCor--currently undergoing clinical trials in the United States--allows the patient to be completely mobile. The lack of transcutaneous wires also eliminates the primary source of the infections that have plagued TAH patients in the past. Though it is not without drawbacks, the AbioCor could represent a crucial advance in TAH technology. In this Technology Overview, we describe the operation of the AbioCor and discuss its likely impact on hospitals if it is approved for marketing in the United States. We also discuss a related cardiac-support technology: ventricular assist devices (VADs), which may also be used for permanent cardiac support someday.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Hospitals-II
Nurses that work in hospitals have...
Hospitals-I
Heart Failure V: Medical Management
Integrated Healthcare System
Cardiac Catheterization IV: Nursing Management

